Insider · CIK 0001965964
Yu-Hsin Lin
Files at BLTE (BELITE BIO, INC). First filing Apr 13, 2026, latest Sep 9, 2026.
Yu-Hsin Lin files SEC Form 4 as CEO and director at BLTE (BELITE BIO, INC). Since Apr 13, 2026, Yu-Hsin Lin has reported 0 open-market buys worth $0 and 2 open-market sells worth $21M, the latest filed on Sep 9, 2026.
A track record needs three past buys with six months of prices behind them; Yu-Hsin Lin has 0, so none is measured yet.
The newest scored trade: sold $19M of BLTE on Sep 4, 2026, filed Sep 9, 2026, scored 58 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $21M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BLTE: BELITE BIO, INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | BELITE BIO, INC | $19M 100,435 shares | -59% | - | |
| 45Moderate | BELITE BIO, INC | $1.7M 9,200 shares | -5% | +231% from low-5% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 18, 2025 | BLTE Belite Bio, Inc. | 96,950 0.30% of outstanding | $7.1M | Sep 18, 2025 | $72k |
| May 21, 2025 | BLTE Belite Bio, Inc. | 120,400 0.37% of outstanding | $7.8M | May 21, 2025 | $3.7M |
| Jan 2, 2025 | BLTE Belite Bio, Inc. | 162,000 0.56% of outstanding | $10M | Jan 2, 2025 | $2.2M |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -2,635 | $180.29 | $475k | 167,934 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -2,587 | $181.24 | $469k | 165,347 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -3,413 | $182.50 | $623k | 161,934 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -4,955 | $183.30 | $908k | 156,979 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -6,252 | $184.52 | $1.2M | 150,727 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -4,593 | $185.34 | $851k | 146,134 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -7,800 | $186.32 | $1.5M | 138,334 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -6,200 | $187.25 | $1.2M | 132,134 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -3,045 | $188.26 | $573k | 129,089 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -8,955 | $189.34 | $1.7M | 120,134 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -600 | $190.39 | $114k | 119,534 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -11,080 | $191.15 | $2.1M | 108,454 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -4,209 | $192.54 | $810k | 104,245 | 34 d ago |
| Sep 4, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -8,111 | $193.13 | $1.6M | 96,134 | 34 d ago |
| Sep 8, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -2,400 | $194.33 | $466k | 93,734 | 34 d ago |
| Sep 8, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -6,090 | $195.62 | $1.2M | 87,644 | 34 d ago |
| Sep 8, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -6,058 | $196.54 | $1.2M | 81,586 | 34 d ago |
| Sep 8, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -8,752 | $197.36 | $1.7M | 72,834 | 34 d ago |
| Sep 8, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -2,700 | $198.09 | $535k | 70,134 | 34 d ago |
| Apr 21, 2026 | BLTE BELITE BIO, INC | JOther Ordinary Share | +10,000 | $0.00 | $0 | 182,949 | Apr 23, 2026 |
| Apr 9, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -2,500 | $180.36 | $451k | 177,634 | Apr 13, 2026 |
| Apr 9, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -3,500 | $181.33 | $635k | 174,134 | Apr 13, 2026 |
| Apr 9, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -3,000 | $182.40 | $547k | 171,134 | Apr 13, 2026 |
| Apr 9, 2026 | BLTE BELITE BIO, INC | SOpen-market sale American depositary share10b5-1 | -200 | $183.00 | $37k | 170,934 | Apr 13, 2026 |
| Mar 31, 2026 | BLTE BELITE BIO, INC | AGrant or award Stock Option (right to buy)derivative | +206,954 | $0.00 | $0 | 413,908 | Apr 2, 2026 |
Questions about Yu-Hsin Lin
Answered from the filings on this page, as of the latest one.
Is Yu-Hsin Lin buying or selling?
In the last 12 months Yu-Hsin Lin reported 0 open-market buys worth $0 and 2 open-market sells worth $21M on SEC Form 4; the latest was sold $19M of BLTE on Sep 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Yu-Hsin Lin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yu-Hsin Lin has 0.
Where does Yu-Hsin Lin file Form 4?
Yu-Hsin Lin has filed Form 4 at BLTE (BELITE BIO, INC) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.